Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
Natera will present 35 studies at the 2026 ASCO Annual Meeting, including 3 oral presentations, highlighting its leadership in molecular residual disease (MRD) testing. A large real-world meta-analysis of Signatera across 3,000+ patients and 15 tumor types showed Signatera-positivity was strongly associated with recurrence risk, with hazard ratios of 8.15 in the adjuvant setting and 18.30 in surveillance.
Key figures
- Abstract count
- 35
- Oral presentations
- 3
- Adjuvant hazard ratio
- 8.15
- Crc chemo hazard ratio
- 0.3
- Meta analysis patients
- 3000
- Meta analysis tumor types
- 15
- Surveillance hazard ratio
- 18.3
- Follicular lymphoma pfs mrd neg
- 81%
- Follicular lymphoma pfs mrd pos
- 56%
- Nsclc ctdna preceded recurrence
- 94%
- Nsclc ctdna clearance no recurrence
- 100%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.